Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Share-based Compensation (2020 - 2025)

Neuroone Medical Technologies' Share-based Compensation history spans 7 years, with the latest figure at $359255.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 5.9% year-over-year to $359255.0; the TTM value through Dec 2025 reached $1.3 million, down 6.58%, while the annual FY2025 figure was $1.3 million, 5.94% down from the prior year.
  • Share-based Compensation reached $359255.0 in Q4 2025 per NMTC's latest filing, roughly flat from $358560.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $878852.0 in Q2 2021 to a low of $203072.0 in Q4 2021.
  • Average Share-based Compensation over 5 years is $328418.9, with a median of $312646.0 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: plummeted 70.92% in 2022, then skyrocketed 50.18% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $203072.0 in 2021, then soared by 47.82% to $300181.0 in 2022, then rose by 2.82% to $308638.0 in 2023, then rose by 9.91% to $339224.0 in 2024, then rose by 5.9% to $359255.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Share-based Compensation are $359255.0 (Q4 2025), $358560.0 (Q3 2025), and $316654.0 (Q2 2025).